Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/12315
Full metadata record
DC FieldValueLanguage
dc.contributor.authorCheung, Ada Sen
dc.contributor.authorZajac, Jeffrey Den
dc.contributor.authorGrossmann, Mathisen
dc.date.accessioned2015-05-16T01:58:47Z
dc.date.available2015-05-16T01:58:47Z
dc.date.issued2014-07-23en
dc.identifier.citationEndocrine-related Cancer 2014; 21(5): R371-94en
dc.identifier.govdoc25056176en
dc.identifier.otherPUBMEDen
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/12315en
dc.description.abstractProstate cancer and treatment with androgen deprivation therapy (ADT) affect significant numbers of the male population. Endocrine effects of ADT are a critical consideration in balancing the benefits and risks of treatment on long-term survival and quality of life. This review highlights the latest advances in androgen manipulation in prostate cancer with an emphasis on the effects of ADT on muscle and bone, which universally affects the health and well-being of men undergoing ADT for prostate cancer. Muscle mass declines with ADT; however, the evidence that this correlates with a decrease in muscle strength or a decrease in physical performance is discordant. Cortical bone decay also occurs in association with an increase in fracture risk, hence optimization of musculoskeletal health in men undergoing ADT is crucial. The role of exercise, and current and emerging anabolic therapies for muscle as well as various new strategies to prevent loss of bone mass in men undergoing ADT are discussed. Future well-designed, prospective, controlled studies are required to elucidate the effects of ADT on physical performance, which are currently lacking, and larger randomized controlled trials are required to test the efficacy of medical therapies and exercise interventions to target proven deficits and to ensure safety in men with prostate cancer.en
dc.language.isoenen
dc.subject.otherandrogen deprivationen
dc.subject.othercardiovascular diseasesen
dc.subject.othermuscleen
dc.subject.otherosteoporosisen
dc.subject.otherprostatic neoplasmsen
dc.subject.otherAndrogen Antagonists.adverse effectsen
dc.subject.otherAnimalsen
dc.subject.otherAntineoplastic Agents, Hormonal.adverse effectsen
dc.subject.otherBone Diseases.chemically induced.drug therapyen
dc.subject.otherBone and Bones.drug effects.metabolismen
dc.subject.otherHumansen
dc.subject.otherMaleen
dc.subject.otherMuscle, Skeletal.drug effects.metabolismen
dc.subject.otherMuscular Atrophy.drug therapyen
dc.subject.otherProstatic Neoplasms.drug therapyen
dc.titleMuscle and bone effects of androgen deprivation therapy: current and emerging therapies.en
dc.typeJournal Articleen
dc.identifier.journaltitleEndocrine-related canceren
dc.identifier.affiliationDepartment of EndocrinologyAustin Health, Heidelberg, Victoria, AustraliDepartment of Medicine (Austin Health)The University of Melbourne, 300 Waterdale Road, Heidelberg West, Victoria 3081, Australia Department of EndocrinologyAustin Health, Heidelberg, Victoria, AustraliDepartment of Medicine (Austin Health)The University of Melbourne, 300 Waterdale Road, Heidelberg West, Victoria 3081, Australiaen
dc.identifier.doi10.1530/ERC-14-0172en
dc.description.pagesR371-94en
dc.relation.urlhttps://pubmed.ncbi.nlm.nih.gov/25056176en
dc.type.austinJournal Articleen
local.name.researcherCheung, Ada S
item.openairetypeJournal Article-
item.cerifentitytypePublications-
item.grantfulltextnone-
item.fulltextNo Fulltext-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.languageiso639-1en-
crisitem.author.deptEndocrinology-
crisitem.author.deptMedicine (University of Melbourne)-
crisitem.author.deptEndocrinology-
crisitem.author.deptMedicine (University of Melbourne)-
crisitem.author.deptEndocrinology-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

60
checked on Nov 27, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.